Detection of replication competent retrovirus and lentivirus.

Lakshmi Sastry, Kenneth Cornetta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Retroviral vectors based on murine leukemia viruses (MuLV) have been used in clinical investigations for over a decade. Alternative retroviruses, most notably vectors based on HIV-1 and other lentiviruses, are now entering into clinical trials. Although vectors are designed to be replication defective, recombination events during vector production could lead to the generation of replication competent retroviruses (RCR) or replication competent lentiviruses (RCL). Careful screening of vector prior to human use must insure that patients are not inadvertently exposed to RCR or RCL. We describe methods capable of detecting low levels of virus contamination and discuss the current regulatory guidelines for screening gene therapy products intended for human use.

Original languageEnglish
Pages (from-to)243-263
Number of pages21
JournalMethods in molecular biology (Clifton, N.J.)
Volume506
StatePublished - 2009

Fingerprint

Lentivirus
Retroviridae
Murine Leukemia Viruses
Genetic Therapy
Genetic Recombination
HIV-1
Clinical Trials
Guidelines
Viruses

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Detection of replication competent retrovirus and lentivirus. / Sastry, Lakshmi; Cornetta, Kenneth.

In: Methods in molecular biology (Clifton, N.J.), Vol. 506, 2009, p. 243-263.

Research output: Contribution to journalArticle

@article{61a67d8711274ccfb5743bcbd4d62d08,
title = "Detection of replication competent retrovirus and lentivirus.",
abstract = "Retroviral vectors based on murine leukemia viruses (MuLV) have been used in clinical investigations for over a decade. Alternative retroviruses, most notably vectors based on HIV-1 and other lentiviruses, are now entering into clinical trials. Although vectors are designed to be replication defective, recombination events during vector production could lead to the generation of replication competent retroviruses (RCR) or replication competent lentiviruses (RCL). Careful screening of vector prior to human use must insure that patients are not inadvertently exposed to RCR or RCL. We describe methods capable of detecting low levels of virus contamination and discuss the current regulatory guidelines for screening gene therapy products intended for human use.",
author = "Lakshmi Sastry and Kenneth Cornetta",
year = "2009",
language = "English",
volume = "506",
pages = "243--263",
journal = "Methods in Molecular Biology",
issn = "1064-3745",
publisher = "Humana Press",

}

TY - JOUR

T1 - Detection of replication competent retrovirus and lentivirus.

AU - Sastry, Lakshmi

AU - Cornetta, Kenneth

PY - 2009

Y1 - 2009

N2 - Retroviral vectors based on murine leukemia viruses (MuLV) have been used in clinical investigations for over a decade. Alternative retroviruses, most notably vectors based on HIV-1 and other lentiviruses, are now entering into clinical trials. Although vectors are designed to be replication defective, recombination events during vector production could lead to the generation of replication competent retroviruses (RCR) or replication competent lentiviruses (RCL). Careful screening of vector prior to human use must insure that patients are not inadvertently exposed to RCR or RCL. We describe methods capable of detecting low levels of virus contamination and discuss the current regulatory guidelines for screening gene therapy products intended for human use.

AB - Retroviral vectors based on murine leukemia viruses (MuLV) have been used in clinical investigations for over a decade. Alternative retroviruses, most notably vectors based on HIV-1 and other lentiviruses, are now entering into clinical trials. Although vectors are designed to be replication defective, recombination events during vector production could lead to the generation of replication competent retroviruses (RCR) or replication competent lentiviruses (RCL). Careful screening of vector prior to human use must insure that patients are not inadvertently exposed to RCR or RCL. We describe methods capable of detecting low levels of virus contamination and discuss the current regulatory guidelines for screening gene therapy products intended for human use.

UR - http://www.scopus.com/inward/record.url?scp=60749111065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749111065&partnerID=8YFLogxK

M3 - Article

C2 - 19110631

AN - SCOPUS:60749111065

VL - 506

SP - 243

EP - 263

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

SN - 1064-3745

ER -